YBCMD-01840; No. of pages: 7; 4C: Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Contents lists available at ScienceDirect
Blood Cells, Molecules and Diseases journal homepage: www.elsevier.com/locate/bcmd
Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia Mansi Arora a, Deepak Kaul a,⁎, Neelam Varma b, R.K. Marwaha c a b c
Department of Experimental Medicine & Biotechnology, Post-Graduate Institute of Medical Education & Research, Chandigarh 160012, India Department of Hematology, Post-graduate Institute of Medical Education & Research, Chandigarh 160012, India Department of Pediatrics, Post-graduate Institute of Medical Education & Research, Chandigarh 160012, India
a r t i c l e
i n f o
Article history: Submitted 29 May 2014 Available online xxxx (Communicated by Mohandas Narla, 15 Jul 2014) Keywords: Human PBMCs MALT1 CYLD cleavage Transformation Pediatric T-ALL
a b s t r a c t There exists a general recognition of the fact that post translational modification of CYLD protein through proteolytic cleavage by MALT-1 results in sustained cellular NF-kB activity which is conspicuously found to be associated with cancer in general and hematological malignancies in particular. The present study was directed to understand the contribution of MALT-1 and deubiquitinase CYLD to the initiation of T-cell acute lymphoblastic leukemia (T-ALL). Such a study revealed for the first time that the 35 kDa CYLD cleaved factor generated by MALT-1 mediated proteolytic cleavage was conspicuously present in human T- ALL subjects of pediatric age group. Further, over-expression of this 35 kDa CYLD factor within normal human peripheral blood mononuclear cells had the inherent capacity to program the genome of these cells resulting in T-cell lineage ALL. Based upon these results, we propose that MALT1 inhibitors may be of crucial importance in the treatment of T-ALL subjects of pediatric age group. © 2014 Published by Elsevier Inc.
Introduction
Material and methods
Several studies have demonstrated a crucial involvement of both canonical and non-canonical NFkB activation in the evolution of human hematological malignancies [1]. Such NFkB pathways have been found downstream of oncogenic Notch-I responsible for thymocyte neoplastic disease known as T-cell acute lymphoblastic leukemia [1,2]. It has been recently demonstrated that Notch through Hes 1, a canonical Notch target and transcriptional repressor, sustains NFkB activation by repressing the deubiquitinase CYLD [2]. Cylindromatosis (CYLD), a tumor suppressor gene, has been shown to regulate the activity of NFkB within human cells. Post-translational modifications of CYLD including phosphorylation, ubiquitination and proteolytic cleavage appear to be critical for its function [3–5]. The para-caspase mucosa associated lymphoid tissue (MALT-1) has recently emerged as the most critical regulator of CYLDmediated NFkB activation in various immune and non-immune cells [6–8]. In this context, the present study was addressed to understand three specific issues: 1) how MALT-1 over-expression within human blood mononuclear cells programs these cells?; 2) does MALT-1 induced CYLD-cleavage govern this transformation?; and 3) does similar CYLD post-translational modification occur in T-cells derived from acute lymphoblastic leukemia subjects of pediatric age-group?
Cell culture
⁎ Corresponding author. Fax: +91 172 2744401. E-mail address: [email protected] (D. Kaul).
Normal peripheral blood mononuclear cells (PBMCs) were isolated from blood withdrawn from 15 normal healthy volunteers (with their prior informed consent ensuring that these subjects had abstained from any medication for 2 weeks before blood donation) using density gradient centrifugation method and cultured as described before [9]. T-cells were isolated by MACS separation according to the manufacturer's protocol (Miltenyi Biotec, Germany). Freshly diagnosed T-ALL patient subjects of pediatric age group (n = 15) were employed from the outpatient department (OPD) of Pediatrics of our institute with their prior informed consent and ethical approval by institute's ethical committee. Further, the study conforms to the principles outlined in the declaration of Helsinki [10]. Transfection p3F-Strep-mMALT1 obtained from “Addgene plasmid 33315” [11] was transfected into PBMCs using ESCORT transfection reagent (Sigma) to overexpress MALT1 protein. siRNA against conserved sequence of MALT1 mRNA (Sigma) was used to knock-down the expression of MALT1. The sequences corresponding to the MALT1 cleaved CYLD— 35 kDa and 70 kDa, were amplified using specific designed primers and the PCR amplicons were cloned in a pEF6V5His TOPO expression vector
http://dx.doi.org/10.1016/j.bcmd.2014.07.008 1079-9796/© 2014 Published by Elsevier Inc.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
2
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 1. MALT1 dependent transformation of normal human PBMCs: Ectopic MALT1 over-expression using a specific MALT1 expression plasmid & its suppression using a specific siRNA against MALT1 mRNA within normal human PBMCs showed significant increase and decrease in the expression of MALT1 gene product respectively (A). (B) Cellular MALT1 overexpression results in increased expression of IL-6 (markers of NF-kB activity) and C-myc (marker of cellular proliferation). The expression of MALT1 positively regulates the entry of normal PBMCs into cell cycle progression (C).
(Invitrogen) and subsequently transfected into normal human PBMCs followed by maintenance of these cells in vitro culture up to 5 days. Expression analysis Transcriptional expression of various genes was analyzed by RT-PCR using gene specific primers. Further the PCR products were run on 2.5% agarose gel and to analyze the relative expression of genes a densitometry scanning of bands was done using scion image analysis software. Immuno-blot analysis and immuno-precipitation Cellular protein was extracted and subsequently subjected to SDSPAGE, followed by western blotting and immuno-detection as per the standard procedure [9] using specific antibodies against MALT1, CYLD (Polyclonal and C terminal) and β-actin obtained from Sigma. Cellular immuno-precipitation experiments were done as described previously [9]. In order to verify the status of NFkB activity, the PBMCs transfected with 35 kDa factor were processed for separation of cytoplasmic and nuclear protein fractions. The cells were suspended in buffer containing 250 mM Sucrose, 20 mM HEPES (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and protease inhibitor cocktail (Sigma) passed through a 25G needle 10 times using a 1 ml syringe and left on ice for 20 min. The nuclear pellet was centrifuged out, washed with buffer and re-suspended in standard lysis buffer with
10% glycerol and 0.1% SDS. The cytoplasmic extract was subjected to ethanol precipitation and further re-suspended in standard lysis buffer. These extracts were immuno-blotted using primary antibodies against Rel A/p65 (Sigma), pIΚBα (Cell Signaling Technologies). β-Actin (Sigma) and histone H3 (Sigma) were used as invariant controls for cytoplasmic and nuclear protein fractions respectively.
Flow cytometry Cells were incubated with combinations of antibodies to cell surface determinants, conjugated to PE, FITC, Cy-Cy-chrome, or biotin. Antibodies specific to the following surface markers were purchased from BD Biosciences: CD1A, CD2, CD3, CD4, CD5, CD8, CD10, CD13, CD20, CD33, CD34, CD38, CD79a, HLADR, and TdT. Biotinylated cells were visualized using streptavidin conjugated to PE or Cy-Cychrome (BD Biosciences). All samples were acquired on BD LSR II (BD Biosciences), and results were analyzed with BD FACSDiva v6 Software (BD Biosciences). Absolute numbers of lymphocyte subpopulations were calculated based on their percentage and the total number of lymphocytes. For cell cycle analysis, cells were permeabilized using 70% ethanol for 2 h and incubated with RNase A at 37 °C for 15 min. Cells were acquired on BD LSR II (BD Biosciences) immediately after staining with propidium iodide (PI). Apoptosis was checked using Annexin V/PI kit (Sigma).
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
3
Fig. 2. Functional significance of MALT1 induced C terminal CYLD cleavage factor—70 kDa. Ectopic MALT1 expression in normal human PBMCs resulted in the cleavage of CYLD protein yielding two factors of molecular weight corresponding to 70 kDa and 35 kDa (A) and this phenomenon was reversed when MALT1 expression was suppressed with the help of siRNA against MALT1 mRNA as compared to control cells showing wild type 105 kDa CYLD. (A). Ectopic expression of 70 kDa (C terminal cleaved factor from CYLD protein) within normal human PBMCs significantly increased the IL-6 expression (B) without any effect on C-myc gene expression (B), cell cycle progression and apoptosis (C).
Sequence analysis
Statistical analysis
The amplicons corresponding to coding region of CYLD gene were amplified by RT-PCR using gene specific primers from total RNA of T-ALL subjects of pediatric age group. These samples were further subjected to DNA sequencing using standard method. The sequence data was further analyzed using clustal X 2.0.12 software.
Statistical analyses were performed by SPSS windows version 19. Data were presented as mean ± S.D. Statistical comparisons were made using Student's t-test, Mann–Whitney U test or ANOVA followed by appropriate post hoc test. Differences were considered significant at p b 0.01.
In-vitro cleavage of protein substrates
Results
PBMCs were transfected with MALT1 and CYLD (C terminal) expression plasmids in separate set of experiments. After 72 h, MALT1 and C terminal CYLD were immuno-precipitated from the corresponding wells using anti-MALT1 and anti-CYLD antibody respectively. The precipitated CYLD protein was diluted to 1 μM final concentration and incubated with active full length MALT1 protein (Immunoprecipitated in previous step) for 1 h at 37 ºC in 20 mM Pipes, 100 mM NaCl, 0.8 M sodium citrate and 10 mM DTT (pH7.2) The reaction was stopped by TCA precipitation. Cleavage was subsequently assessed by SDS-PAGE, followed by western blotting using an anti-CYLD antibody specific to C terminal.
MALT1 over-expression and cellular transformation. Ectopic expression of MALT1 gene within normal human PBMCs not only resulted in significantly increased transcriptional expression of genes coding for c-myc (used as a marker of cellular proliferation) and IL-6 (genomic marker of inflammation) but also about 40 fold increase in the cell cycle progression (Fig. 1A-C) as compared to that observed in the control cells. Further, this phenomenon could be reversed in MALT1 over-expressing PBMCs transfected with siRNA against MALT1 mRNA (Fig. 1A-C) indicating thereby that the observed cell transformation is because of increased MALT1 activity within such cells. The MALT1
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
4
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 3. Functional significance of MALT1 induced N terminal CYLD cleavage factor—35 kDa. Ectopic expression of N terminal 35 kDa factor (derived from CYLD cleavage by MALT1) within normal human PBMCs (A) resulted in significant increase in the expression of genes coding for IL-6, C-myc, Bcl-3, TNF-α, Par-4, AATF, cyclin-E, cyclin-D and notch-1 (C), significant increase in cell cycle progression (B) and increased NFkB activity shown by increased nuclear localization of p65/RelA and increased expression of phosphorylated IΚBα in the cytoplasmic extract (D).
induced increase in IL-6 expression apparently indicated that MALT1 may be responsible for sustained NFκB activity. MALT1 dependent cleavage of CYLD protein and its implications. Since MALT1 is known to cleave CYLD gene product [6,7] and CYLD has been widely recognized to inhibit NFkB activity [3,12,13], we attempted to explore whether or not CYLD cleavage by MALT1 is responsible for the observed transformation of human normal PBMCs. Ectopic MALT1 expression within normal human PBMCs resulted in cleavage of CYLD protein into two factors corresponding to molecular weight of about 70 kDa and 35 kDa and this CYLD cleavage was prevented in MALT1 over-expressing PBMCs transfected with siRNA against MALT1 mRNA (Fig. 2A). Therefore, a full length 110 kDa CYLD protein band was obtained in the latter case. In order to explore the functional implication of these two factors 70 kDa and 35 kDa generated through the cleavage of CYLD protein by MALT1, we cloned the cDNA sequences coding for these factors in pEF6V5His TOPO expression vector and each vector was subsequently transfected (in independent experiments) in the normal PBMCs maintained in vitro culture. Transfection of human PBMCs with C terminal 70 kDa CYLD encoding plasmid resulted in significant increased
expression of this factor in these cells and this phenomenon was accompanied by increased expression of IL-6 gene without any significant effect upon expression of c-myc gene, cell cycle progression or apoptosis (Fig. 2B, C). However, ectopic expression of N terminal 35 kDa CYLD factor (Fig. 3A) within human normal PBMCs resulted in a significant increase in the S phase of the cell cycle (Fig. 3B) and expression of genes associated with inflammation and proliferation like IL-6, c-myc, TNFα, Par-4, AATF, Cyclin-E, Cyclin-D, and Notch1 (aberrant T-cell signaling) (Fig. 3C). A significant increase in the nuclear translocation of Rel A/p65 and cytoplasmic expression of phosphorylated IΚBα further confirmed an aberrant activation of NFkB transcription factor (Fig. 3D). Upon microscopic examination, these PBMCs showed peculiar changes in their morphology including lympho-blast like characteristics with immature nucleus (data not shown). The flow cytometric-immuno phenotypic analysis (based upon the 20% cut off threshold) showed markers positive for T-cell lineage leukemia (CD2, CD3, CCD3, CD4, CD5, CD8, CD19, and CD20), immaturity (TdT, HLA-DR) and negative for B- and myeloid lineage (Fig. 4 and Supplementary Fig. 1) as compared to the corresponding controls cells thereby indicating that observed cellular transformation is attributed to N terminal 35 kDa cleaved factor generated through MALT1 action on CYLD protein.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
Fig. 4. Immuno-phenotypic analysis of PBMCs displaying ectopic expression of 35 kDa factor (derived from CYLD cleavage by MALT1). N terminal 35 kDa factor overexpressing normal human PBMCs were maintained in vitro culture for 5 days and subsequently their phenotypic characteristics were probed using several surface markers like CD1A, CD2, CD3, CCD3, CD4, CD5, CD8, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD79a, CD117, HLADR and TdT with respect to their corresponding controls.
5
6
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 5. Nature of MALT1 & CYLD gene expression in human T-ALL pediatric subjects. The PBMCs derived from T-ALL patients of pediatric age group not only exhibited significantly high expression of MALT1 gene (A) but also conspicuous presence of 35 kDa CYLD protein (B). In order to prove that this observed factor of 35 kDa results from the double cleavage of CYLD protein by MALT1 yielding 70 kDa factor and subsequently 35 kDa factor, the purified MALT1 was incubated with wild type CYLD protein as well as 70 kDa factor derived from CYLD and subsequently the proteolytic fragments were examined by western immuno-blotting using C terminal anti-CYLD antibody (C).
Verification of observed phenotypic changes in T-ALL patient samples The observed genomic and immuno-phenotypic changes in the cells transfected with N-terminal 35 kDa CYLD factor implicated induction of T-cell lineage lymphoblastic leukemia. To verify this observation 15 freshly diagnosed T-cell lineage ALL subjects of pediatric age group were employed in the study. The translational product of CYLD gene within these patients revealed a conspicuous 35 kDa CYLD protein instead of wild type 110 kDa CYLD found in the normal cells (Fig. 5B). Further, these acute lymphoblastic leukemic T-cells also exhibited significantly high expression of MALT1 gene (Fig. 5A). Consequently, it was logical to assume that this observed 35 kDa cleaved CYLD factor in T-cell ALL could have been generated because of intrinsic high expression of MALT1 gene observed in these cells. This view was further strengthened by the observation that there was no mutation observed at DNA level in the full length CYLD gene in these T-ALL subjects (Data not shown). In order to further confirm that the observed 35 kDa cleaved factor is generated through the action of MALT1 on CYLD protein, we studied the enzymatic activity of MALT1 protein on native 110 kDa CYLD as well as its C terminal 70 kDa cleaved factor. The results of this study revealed that MALT1 cleaves CYLD protein at two positions to generate a conglomerate of 35 kDa cleaved factors (Fig. 5C) and it is the N terminal 35 kDa fragment that is responsible for programming the normal human PBMCs to T-cell lymphoblastic leukemia. This further proves our observation that CYLD cleaved factor of 35 kDa (N terminal) has the potential to induce and initiate leukemogenesis in normal T cells. Discussion MALT1 has emerged as a crucial mediator of TCR and BCR- dependent lymphocyte activation and deregulation of this phenomenon can cause many human diseases including leukemia and lymphoma [1,7].
Furthermore, MALT1 has proteolytic activity that contributes to the cleavage of CYLD which is a deubiquitinating enzyme that is integral to NFκB signaling [6,14]. Several studies have confirmed that NFκB has the inherent capacity to act as an important regulator of cell survival, proliferation and differentiation thereby recognized to be involved in malignant transformation [1,2,15–17]. Therefore, the fact that CYLD protein exerts tight regulation of NFκB activity assumes great importance. Recently oncogenic Notch dependent activation of NFκB has been proposed to be responsible for progression of T-ALL [2]. It is in this context that the present study assumes importance as ectopic expression of MALT1 in normal human PBMCs could transform these cells [18] and this phenomenon was mediated by the ability of MALT1 to cleave CYLD in order to generate 35 kDa N-terminal factor (Fig. 2). Ectopic expression of N terminal 35 kDa fragment (generated by MALT1 proteolytic action on CYLD protein) within normal human PBMCs was sufficient not only to simulate the same phenomenon induced by ectopic expression of MALT1 in human PBMCs (Fig. 1) but also to transform normal human PBMCs into T-ALL like cells with typical signatures (Fig. 3, 4) [19]. Further, increased expression of MALT1 gene as well as existence of 35 kDa CYLD cleaved factor was conspicuously found in all the pediatric T-ALL subjects employed in the present study (Fig. 5A,B). On the basis of these results, it is not unlikely that post-translational modification of CYLD protein through proteolysis by MALT1 leading to the generation of 35 kDa N-terminal factor may be crucial in initiating human T-cell lymphoblastic leukemia. Though Stall et al. have shown aberrant up-regulation of NFkB activity in cells lacking wild type CYLD but here for the first time we show that it is not mere absence of CYLD but the presence of the N terminal 35 kDa cleavage factor which leads to induction of T-cell leukemogenic state. Though the exact mechanism behind initiation of T-ALL via this 35 kDa N terminal factor is not clear, the presence of an intact CAP-Gly domain could possibly allow it to
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
compete with wild type functional CYLD in binding with NEMO/IKKϒ thus resulting in constitutive NFkB activity. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bcmd.2014.07.008. Conflict of interest It is to certify that there is no conflict of interest including any financial, personal or other relationship with other people or organization. Acknowledgments Assistance by Ms. Sugandha Sharma during the course of this work is highly acknowledged. This work was supported by inhouse funding of Molecular Biology Unit, Department of Experimental Medicine and Biotechnology, PGIMER under grant number EMB2014/3450 as well as the UGC fellowship grant awarded to Ms. Mansi Arora via UNIGRANTS/F.2-18.98 (SA-I). References [1] L. Espinosa, S. Cathelin, T. D'Altri, T. Trimarchi, A. Statnikov, J. Guiu, et al., The Notch/ Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia, Cancer Cell 18 (2010) 268–281, http://dx.doi.org/10.1016/j.ccr.2010.08.006. [2] J.C. Aster, S.C. Blacklow, W.S. Pear, Notch signalling in T-cell lymphoblastic leukaemia/ lymphoma and other haematological malignancies, J. Pathol. 223 (2011) 262–273, http://dx.doi.org/10.1002/path.2789. [3] A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, G. Courtois, The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination, Nature 424 (2003) 801–805, http://dx.doi.org/10.1038/nature01802. [4] S.F. Moss, M.J. Blaser, Mechanisms of disease: inflammation and the origins of cancer, Nat. Clin. Pract. Oncol. 2 (2005) 90–97, http://dx.doi.org/10.1038/ ncponc0081 (quiz 1 p following 113). [5] W.W. Reiley, M. Zhang, W. Jin, M. Losiewicz, K.B. Donohue, C.C. Norbury, et al., Regulation of T cell development by the deubiquitinating enzyme CYLD, Nat. Immunol. 7 (2006) 411–417, http://dx.doi.org/10.1038/ni1315.
7
[6] J. Hachmann, S.J. Snipas, B.J. van Raam, E.M. Cancino, E.J. Houlihan, M. Poreba, et al., Mechanism and specificity of the human paracaspase MALT1, Biochem. J. 443 (2012) 287–295, http://dx.doi.org/10.1042/BJ20120035. [7] J. Staal, Y. Driege, T. Bekaert, A. Demeyer, D. Muyllaert, P. Van Damme, et al., T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1, EMBO J. 30 (2011) 1742–1752, http://dx.doi.org/10.1038/emboj.2011.85. [8] S.-C. Sun, CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes, Cell Death Differ. 17 (2010) 25–34, http://dx.doi. org/10.1038/cdd.2009.43. [9] M. Sharma, S. Sharma, M. Arora, D. Kaul, Regulation of cellular cyclin D1 gene by arsenic is mediated through miR-2909, Gene 522 (2013) 60–64, http://dx.doi.org/ 10.1016/j.gene.2013.03.058. [10] J.R. Williams, The Declaration of Helsinki and public health, Bull. World Health Organ. 86 (2008) 650–652, http://dx.doi.org/10.2471/BLT.08.050955. [11] C.C. Stempin, L. Chi, J.P. Giraldo-Vela, A.A. High, H. Häcker, V. Redecke, The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)dependent NF-κB activation, J. Biol. Chem. 286 (2011) 37147–37157, http://dx.doi. org/10.1074/jbc.M111.263384. [12] R. Massoumi, K. Chmielarska, K. Hennecke, A. Pfeifer, R. Fässler, Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling, Cell 125 (2006) 665–677, http://dx.doi.org/10.1016/j.cell.2006.03.041. [13] T.R. Brummelkamp, S.M.B. Nijman, A.M.G. Dirac, R. Bernards, Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB, Nature 424 (2003) 797–801, http://dx.doi.org/10.1038/nature01811. [14] A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, G. Courtois, The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination, Nature 424 (2003) 801–805, http://dx.doi.org/10.1038/nature01802. [15] P.J. Jost, J. Ruland, Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications, Blood 109 (2007) 2700–2707, http://dx.doi. org/10.1182/blood-2006-07-025809. [16] M. Karin, Nuclear factor-kappaB in cancer development and progression, Nature 441 (2006) 431–436, http://dx.doi.org/10.1038/nature04870. [17] P.A. Baeuerle, T. Henkel, Function and activation of NF-kappaB in the immune system, Annu. Rev. Immunol. 12 (1994) 141–179, http://dx.doi.org/10.1146/annurev. iy.12.040194.001041. [18] A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454 (2008) 436–444, http://dx.doi.org/10.1038/nature07205. [19] D. Rauch, S. Gross, J. Harding, S. Bokhari, S. Niewiesk, M. Lairmore, et al., T-cell activation promotes tumorigenesis in inflammation-associated cancer, Retrovirology 6 (2009) 116, http://dx.doi.org/10.1186/1742-4690-6-116.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
Contents lists available at ScienceDirect
Blood Cells, Molecules and Diseases journal homepage: www.elsevier.com/locate/bcmd
Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia Mansi Arora a, Deepak Kaul a,⁎, Neelam Varma b, R.K. Marwaha c a b c
Department of Experimental Medicine & Biotechnology, Post-Graduate Institute of Medical Education & Research, Chandigarh 160012, India Department of Hematology, Post-graduate Institute of Medical Education & Research, Chandigarh 160012, India Department of Pediatrics, Post-graduate Institute of Medical Education & Research, Chandigarh 160012, India
a r t i c l e
i n f o
Article history: Submitted 29 May 2014 Available online xxxx (Communicated by Mohandas Narla, 15 Jul 2014) Keywords: Human PBMCs MALT1 CYLD cleavage Transformation Pediatric T-ALL
a b s t r a c t There exists a general recognition of the fact that post translational modification of CYLD protein through proteolytic cleavage by MALT-1 results in sustained cellular NF-kB activity which is conspicuously found to be associated with cancer in general and hematological malignancies in particular. The present study was directed to understand the contribution of MALT-1 and deubiquitinase CYLD to the initiation of T-cell acute lymphoblastic leukemia (T-ALL). Such a study revealed for the first time that the 35 kDa CYLD cleaved factor generated by MALT-1 mediated proteolytic cleavage was conspicuously present in human T- ALL subjects of pediatric age group. Further, over-expression of this 35 kDa CYLD factor within normal human peripheral blood mononuclear cells had the inherent capacity to program the genome of these cells resulting in T-cell lineage ALL. Based upon these results, we propose that MALT1 inhibitors may be of crucial importance in the treatment of T-ALL subjects of pediatric age group. © 2014 Published by Elsevier Inc.
Introduction
Material and methods
Several studies have demonstrated a crucial involvement of both canonical and non-canonical NFkB activation in the evolution of human hematological malignancies [1]. Such NFkB pathways have been found downstream of oncogenic Notch-I responsible for thymocyte neoplastic disease known as T-cell acute lymphoblastic leukemia [1,2]. It has been recently demonstrated that Notch through Hes 1, a canonical Notch target and transcriptional repressor, sustains NFkB activation by repressing the deubiquitinase CYLD [2]. Cylindromatosis (CYLD), a tumor suppressor gene, has been shown to regulate the activity of NFkB within human cells. Post-translational modifications of CYLD including phosphorylation, ubiquitination and proteolytic cleavage appear to be critical for its function [3–5]. The para-caspase mucosa associated lymphoid tissue (MALT-1) has recently emerged as the most critical regulator of CYLDmediated NFkB activation in various immune and non-immune cells [6–8]. In this context, the present study was addressed to understand three specific issues: 1) how MALT-1 over-expression within human blood mononuclear cells programs these cells?; 2) does MALT-1 induced CYLD-cleavage govern this transformation?; and 3) does similar CYLD post-translational modification occur in T-cells derived from acute lymphoblastic leukemia subjects of pediatric age-group?
Cell culture
⁎ Corresponding author. Fax: +91 172 2744401. E-mail address: [email protected] (D. Kaul).
Normal peripheral blood mononuclear cells (PBMCs) were isolated from blood withdrawn from 15 normal healthy volunteers (with their prior informed consent ensuring that these subjects had abstained from any medication for 2 weeks before blood donation) using density gradient centrifugation method and cultured as described before [9]. T-cells were isolated by MACS separation according to the manufacturer's protocol (Miltenyi Biotec, Germany). Freshly diagnosed T-ALL patient subjects of pediatric age group (n = 15) were employed from the outpatient department (OPD) of Pediatrics of our institute with their prior informed consent and ethical approval by institute's ethical committee. Further, the study conforms to the principles outlined in the declaration of Helsinki [10]. Transfection p3F-Strep-mMALT1 obtained from “Addgene plasmid 33315” [11] was transfected into PBMCs using ESCORT transfection reagent (Sigma) to overexpress MALT1 protein. siRNA against conserved sequence of MALT1 mRNA (Sigma) was used to knock-down the expression of MALT1. The sequences corresponding to the MALT1 cleaved CYLD— 35 kDa and 70 kDa, were amplified using specific designed primers and the PCR amplicons were cloned in a pEF6V5His TOPO expression vector
http://dx.doi.org/10.1016/j.bcmd.2014.07.008 1079-9796/© 2014 Published by Elsevier Inc.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
2
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 1. MALT1 dependent transformation of normal human PBMCs: Ectopic MALT1 over-expression using a specific MALT1 expression plasmid & its suppression using a specific siRNA against MALT1 mRNA within normal human PBMCs showed significant increase and decrease in the expression of MALT1 gene product respectively (A). (B) Cellular MALT1 overexpression results in increased expression of IL-6 (markers of NF-kB activity) and C-myc (marker of cellular proliferation). The expression of MALT1 positively regulates the entry of normal PBMCs into cell cycle progression (C).
(Invitrogen) and subsequently transfected into normal human PBMCs followed by maintenance of these cells in vitro culture up to 5 days. Expression analysis Transcriptional expression of various genes was analyzed by RT-PCR using gene specific primers. Further the PCR products were run on 2.5% agarose gel and to analyze the relative expression of genes a densitometry scanning of bands was done using scion image analysis software. Immuno-blot analysis and immuno-precipitation Cellular protein was extracted and subsequently subjected to SDSPAGE, followed by western blotting and immuno-detection as per the standard procedure [9] using specific antibodies against MALT1, CYLD (Polyclonal and C terminal) and β-actin obtained from Sigma. Cellular immuno-precipitation experiments were done as described previously [9]. In order to verify the status of NFkB activity, the PBMCs transfected with 35 kDa factor were processed for separation of cytoplasmic and nuclear protein fractions. The cells were suspended in buffer containing 250 mM Sucrose, 20 mM HEPES (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and protease inhibitor cocktail (Sigma) passed through a 25G needle 10 times using a 1 ml syringe and left on ice for 20 min. The nuclear pellet was centrifuged out, washed with buffer and re-suspended in standard lysis buffer with
10% glycerol and 0.1% SDS. The cytoplasmic extract was subjected to ethanol precipitation and further re-suspended in standard lysis buffer. These extracts were immuno-blotted using primary antibodies against Rel A/p65 (Sigma), pIΚBα (Cell Signaling Technologies). β-Actin (Sigma) and histone H3 (Sigma) were used as invariant controls for cytoplasmic and nuclear protein fractions respectively.
Flow cytometry Cells were incubated with combinations of antibodies to cell surface determinants, conjugated to PE, FITC, Cy-Cy-chrome, or biotin. Antibodies specific to the following surface markers were purchased from BD Biosciences: CD1A, CD2, CD3, CD4, CD5, CD8, CD10, CD13, CD20, CD33, CD34, CD38, CD79a, HLADR, and TdT. Biotinylated cells were visualized using streptavidin conjugated to PE or Cy-Cychrome (BD Biosciences). All samples were acquired on BD LSR II (BD Biosciences), and results were analyzed with BD FACSDiva v6 Software (BD Biosciences). Absolute numbers of lymphocyte subpopulations were calculated based on their percentage and the total number of lymphocytes. For cell cycle analysis, cells were permeabilized using 70% ethanol for 2 h and incubated with RNase A at 37 °C for 15 min. Cells were acquired on BD LSR II (BD Biosciences) immediately after staining with propidium iodide (PI). Apoptosis was checked using Annexin V/PI kit (Sigma).
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
3
Fig. 2. Functional significance of MALT1 induced C terminal CYLD cleavage factor—70 kDa. Ectopic MALT1 expression in normal human PBMCs resulted in the cleavage of CYLD protein yielding two factors of molecular weight corresponding to 70 kDa and 35 kDa (A) and this phenomenon was reversed when MALT1 expression was suppressed with the help of siRNA against MALT1 mRNA as compared to control cells showing wild type 105 kDa CYLD. (A). Ectopic expression of 70 kDa (C terminal cleaved factor from CYLD protein) within normal human PBMCs significantly increased the IL-6 expression (B) without any effect on C-myc gene expression (B), cell cycle progression and apoptosis (C).
Sequence analysis
Statistical analysis
The amplicons corresponding to coding region of CYLD gene were amplified by RT-PCR using gene specific primers from total RNA of T-ALL subjects of pediatric age group. These samples were further subjected to DNA sequencing using standard method. The sequence data was further analyzed using clustal X 2.0.12 software.
Statistical analyses were performed by SPSS windows version 19. Data were presented as mean ± S.D. Statistical comparisons were made using Student's t-test, Mann–Whitney U test or ANOVA followed by appropriate post hoc test. Differences were considered significant at p b 0.01.
In-vitro cleavage of protein substrates
Results
PBMCs were transfected with MALT1 and CYLD (C terminal) expression plasmids in separate set of experiments. After 72 h, MALT1 and C terminal CYLD were immuno-precipitated from the corresponding wells using anti-MALT1 and anti-CYLD antibody respectively. The precipitated CYLD protein was diluted to 1 μM final concentration and incubated with active full length MALT1 protein (Immunoprecipitated in previous step) for 1 h at 37 ºC in 20 mM Pipes, 100 mM NaCl, 0.8 M sodium citrate and 10 mM DTT (pH7.2) The reaction was stopped by TCA precipitation. Cleavage was subsequently assessed by SDS-PAGE, followed by western blotting using an anti-CYLD antibody specific to C terminal.
MALT1 over-expression and cellular transformation. Ectopic expression of MALT1 gene within normal human PBMCs not only resulted in significantly increased transcriptional expression of genes coding for c-myc (used as a marker of cellular proliferation) and IL-6 (genomic marker of inflammation) but also about 40 fold increase in the cell cycle progression (Fig. 1A-C) as compared to that observed in the control cells. Further, this phenomenon could be reversed in MALT1 over-expressing PBMCs transfected with siRNA against MALT1 mRNA (Fig. 1A-C) indicating thereby that the observed cell transformation is because of increased MALT1 activity within such cells. The MALT1
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
4
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 3. Functional significance of MALT1 induced N terminal CYLD cleavage factor—35 kDa. Ectopic expression of N terminal 35 kDa factor (derived from CYLD cleavage by MALT1) within normal human PBMCs (A) resulted in significant increase in the expression of genes coding for IL-6, C-myc, Bcl-3, TNF-α, Par-4, AATF, cyclin-E, cyclin-D and notch-1 (C), significant increase in cell cycle progression (B) and increased NFkB activity shown by increased nuclear localization of p65/RelA and increased expression of phosphorylated IΚBα in the cytoplasmic extract (D).
induced increase in IL-6 expression apparently indicated that MALT1 may be responsible for sustained NFκB activity. MALT1 dependent cleavage of CYLD protein and its implications. Since MALT1 is known to cleave CYLD gene product [6,7] and CYLD has been widely recognized to inhibit NFkB activity [3,12,13], we attempted to explore whether or not CYLD cleavage by MALT1 is responsible for the observed transformation of human normal PBMCs. Ectopic MALT1 expression within normal human PBMCs resulted in cleavage of CYLD protein into two factors corresponding to molecular weight of about 70 kDa and 35 kDa and this CYLD cleavage was prevented in MALT1 over-expressing PBMCs transfected with siRNA against MALT1 mRNA (Fig. 2A). Therefore, a full length 110 kDa CYLD protein band was obtained in the latter case. In order to explore the functional implication of these two factors 70 kDa and 35 kDa generated through the cleavage of CYLD protein by MALT1, we cloned the cDNA sequences coding for these factors in pEF6V5His TOPO expression vector and each vector was subsequently transfected (in independent experiments) in the normal PBMCs maintained in vitro culture. Transfection of human PBMCs with C terminal 70 kDa CYLD encoding plasmid resulted in significant increased
expression of this factor in these cells and this phenomenon was accompanied by increased expression of IL-6 gene without any significant effect upon expression of c-myc gene, cell cycle progression or apoptosis (Fig. 2B, C). However, ectopic expression of N terminal 35 kDa CYLD factor (Fig. 3A) within human normal PBMCs resulted in a significant increase in the S phase of the cell cycle (Fig. 3B) and expression of genes associated with inflammation and proliferation like IL-6, c-myc, TNFα, Par-4, AATF, Cyclin-E, Cyclin-D, and Notch1 (aberrant T-cell signaling) (Fig. 3C). A significant increase in the nuclear translocation of Rel A/p65 and cytoplasmic expression of phosphorylated IΚBα further confirmed an aberrant activation of NFkB transcription factor (Fig. 3D). Upon microscopic examination, these PBMCs showed peculiar changes in their morphology including lympho-blast like characteristics with immature nucleus (data not shown). The flow cytometric-immuno phenotypic analysis (based upon the 20% cut off threshold) showed markers positive for T-cell lineage leukemia (CD2, CD3, CCD3, CD4, CD5, CD8, CD19, and CD20), immaturity (TdT, HLA-DR) and negative for B- and myeloid lineage (Fig. 4 and Supplementary Fig. 1) as compared to the corresponding controls cells thereby indicating that observed cellular transformation is attributed to N terminal 35 kDa cleaved factor generated through MALT1 action on CYLD protein.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
Fig. 4. Immuno-phenotypic analysis of PBMCs displaying ectopic expression of 35 kDa factor (derived from CYLD cleavage by MALT1). N terminal 35 kDa factor overexpressing normal human PBMCs were maintained in vitro culture for 5 days and subsequently their phenotypic characteristics were probed using several surface markers like CD1A, CD2, CD3, CCD3, CD4, CD5, CD8, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD79a, CD117, HLADR and TdT with respect to their corresponding controls.
5
6
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
Fig. 5. Nature of MALT1 & CYLD gene expression in human T-ALL pediatric subjects. The PBMCs derived from T-ALL patients of pediatric age group not only exhibited significantly high expression of MALT1 gene (A) but also conspicuous presence of 35 kDa CYLD protein (B). In order to prove that this observed factor of 35 kDa results from the double cleavage of CYLD protein by MALT1 yielding 70 kDa factor and subsequently 35 kDa factor, the purified MALT1 was incubated with wild type CYLD protein as well as 70 kDa factor derived from CYLD and subsequently the proteolytic fragments were examined by western immuno-blotting using C terminal anti-CYLD antibody (C).
Verification of observed phenotypic changes in T-ALL patient samples The observed genomic and immuno-phenotypic changes in the cells transfected with N-terminal 35 kDa CYLD factor implicated induction of T-cell lineage lymphoblastic leukemia. To verify this observation 15 freshly diagnosed T-cell lineage ALL subjects of pediatric age group were employed in the study. The translational product of CYLD gene within these patients revealed a conspicuous 35 kDa CYLD protein instead of wild type 110 kDa CYLD found in the normal cells (Fig. 5B). Further, these acute lymphoblastic leukemic T-cells also exhibited significantly high expression of MALT1 gene (Fig. 5A). Consequently, it was logical to assume that this observed 35 kDa cleaved CYLD factor in T-cell ALL could have been generated because of intrinsic high expression of MALT1 gene observed in these cells. This view was further strengthened by the observation that there was no mutation observed at DNA level in the full length CYLD gene in these T-ALL subjects (Data not shown). In order to further confirm that the observed 35 kDa cleaved factor is generated through the action of MALT1 on CYLD protein, we studied the enzymatic activity of MALT1 protein on native 110 kDa CYLD as well as its C terminal 70 kDa cleaved factor. The results of this study revealed that MALT1 cleaves CYLD protein at two positions to generate a conglomerate of 35 kDa cleaved factors (Fig. 5C) and it is the N terminal 35 kDa fragment that is responsible for programming the normal human PBMCs to T-cell lymphoblastic leukemia. This further proves our observation that CYLD cleaved factor of 35 kDa (N terminal) has the potential to induce and initiate leukemogenesis in normal T cells. Discussion MALT1 has emerged as a crucial mediator of TCR and BCR- dependent lymphocyte activation and deregulation of this phenomenon can cause many human diseases including leukemia and lymphoma [1,7].
Furthermore, MALT1 has proteolytic activity that contributes to the cleavage of CYLD which is a deubiquitinating enzyme that is integral to NFκB signaling [6,14]. Several studies have confirmed that NFκB has the inherent capacity to act as an important regulator of cell survival, proliferation and differentiation thereby recognized to be involved in malignant transformation [1,2,15–17]. Therefore, the fact that CYLD protein exerts tight regulation of NFκB activity assumes great importance. Recently oncogenic Notch dependent activation of NFκB has been proposed to be responsible for progression of T-ALL [2]. It is in this context that the present study assumes importance as ectopic expression of MALT1 in normal human PBMCs could transform these cells [18] and this phenomenon was mediated by the ability of MALT1 to cleave CYLD in order to generate 35 kDa N-terminal factor (Fig. 2). Ectopic expression of N terminal 35 kDa fragment (generated by MALT1 proteolytic action on CYLD protein) within normal human PBMCs was sufficient not only to simulate the same phenomenon induced by ectopic expression of MALT1 in human PBMCs (Fig. 1) but also to transform normal human PBMCs into T-ALL like cells with typical signatures (Fig. 3, 4) [19]. Further, increased expression of MALT1 gene as well as existence of 35 kDa CYLD cleaved factor was conspicuously found in all the pediatric T-ALL subjects employed in the present study (Fig. 5A,B). On the basis of these results, it is not unlikely that post-translational modification of CYLD protein through proteolysis by MALT1 leading to the generation of 35 kDa N-terminal factor may be crucial in initiating human T-cell lymphoblastic leukemia. Though Stall et al. have shown aberrant up-regulation of NFkB activity in cells lacking wild type CYLD but here for the first time we show that it is not mere absence of CYLD but the presence of the N terminal 35 kDa cleavage factor which leads to induction of T-cell leukemogenic state. Though the exact mechanism behind initiation of T-ALL via this 35 kDa N terminal factor is not clear, the presence of an intact CAP-Gly domain could possibly allow it to
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
M. Arora et al. / Blood Cells, Molecules and Diseases xxx (2014) xxx–xxx
compete with wild type functional CYLD in binding with NEMO/IKKϒ thus resulting in constitutive NFkB activity. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bcmd.2014.07.008. Conflict of interest It is to certify that there is no conflict of interest including any financial, personal or other relationship with other people or organization. Acknowledgments Assistance by Ms. Sugandha Sharma during the course of this work is highly acknowledged. This work was supported by inhouse funding of Molecular Biology Unit, Department of Experimental Medicine and Biotechnology, PGIMER under grant number EMB2014/3450 as well as the UGC fellowship grant awarded to Ms. Mansi Arora via UNIGRANTS/F.2-18.98 (SA-I). References [1] L. Espinosa, S. Cathelin, T. D'Altri, T. Trimarchi, A. Statnikov, J. Guiu, et al., The Notch/ Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia, Cancer Cell 18 (2010) 268–281, http://dx.doi.org/10.1016/j.ccr.2010.08.006. [2] J.C. Aster, S.C. Blacklow, W.S. Pear, Notch signalling in T-cell lymphoblastic leukaemia/ lymphoma and other haematological malignancies, J. Pathol. 223 (2011) 262–273, http://dx.doi.org/10.1002/path.2789. [3] A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, G. Courtois, The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination, Nature 424 (2003) 801–805, http://dx.doi.org/10.1038/nature01802. [4] S.F. Moss, M.J. Blaser, Mechanisms of disease: inflammation and the origins of cancer, Nat. Clin. Pract. Oncol. 2 (2005) 90–97, http://dx.doi.org/10.1038/ ncponc0081 (quiz 1 p following 113). [5] W.W. Reiley, M. Zhang, W. Jin, M. Losiewicz, K.B. Donohue, C.C. Norbury, et al., Regulation of T cell development by the deubiquitinating enzyme CYLD, Nat. Immunol. 7 (2006) 411–417, http://dx.doi.org/10.1038/ni1315.
7
[6] J. Hachmann, S.J. Snipas, B.J. van Raam, E.M. Cancino, E.J. Houlihan, M. Poreba, et al., Mechanism and specificity of the human paracaspase MALT1, Biochem. J. 443 (2012) 287–295, http://dx.doi.org/10.1042/BJ20120035. [7] J. Staal, Y. Driege, T. Bekaert, A. Demeyer, D. Muyllaert, P. Van Damme, et al., T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1, EMBO J. 30 (2011) 1742–1752, http://dx.doi.org/10.1038/emboj.2011.85. [8] S.-C. Sun, CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes, Cell Death Differ. 17 (2010) 25–34, http://dx.doi. org/10.1038/cdd.2009.43. [9] M. Sharma, S. Sharma, M. Arora, D. Kaul, Regulation of cellular cyclin D1 gene by arsenic is mediated through miR-2909, Gene 522 (2013) 60–64, http://dx.doi.org/ 10.1016/j.gene.2013.03.058. [10] J.R. Williams, The Declaration of Helsinki and public health, Bull. World Health Organ. 86 (2008) 650–652, http://dx.doi.org/10.2471/BLT.08.050955. [11] C.C. Stempin, L. Chi, J.P. Giraldo-Vela, A.A. High, H. Häcker, V. Redecke, The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)dependent NF-κB activation, J. Biol. Chem. 286 (2011) 37147–37157, http://dx.doi. org/10.1074/jbc.M111.263384. [12] R. Massoumi, K. Chmielarska, K. Hennecke, A. Pfeifer, R. Fässler, Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling, Cell 125 (2006) 665–677, http://dx.doi.org/10.1016/j.cell.2006.03.041. [13] T.R. Brummelkamp, S.M.B. Nijman, A.M.G. Dirac, R. Bernards, Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB, Nature 424 (2003) 797–801, http://dx.doi.org/10.1038/nature01811. [14] A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, G. Courtois, The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination, Nature 424 (2003) 801–805, http://dx.doi.org/10.1038/nature01802. [15] P.J. Jost, J. Ruland, Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications, Blood 109 (2007) 2700–2707, http://dx.doi. org/10.1182/blood-2006-07-025809. [16] M. Karin, Nuclear factor-kappaB in cancer development and progression, Nature 441 (2006) 431–436, http://dx.doi.org/10.1038/nature04870. [17] P.A. Baeuerle, T. Henkel, Function and activation of NF-kappaB in the immune system, Annu. Rev. Immunol. 12 (1994) 141–179, http://dx.doi.org/10.1146/annurev. iy.12.040194.001041. [18] A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454 (2008) 436–444, http://dx.doi.org/10.1038/nature07205. [19] D. Rauch, S. Gross, J. Harding, S. Bokhari, S. Niewiesk, M. Lairmore, et al., T-cell activation promotes tumorigenesis in inflammation-associated cancer, Retrovirology 6 (2009) 116, http://dx.doi.org/10.1186/1742-4690-6-116.
Please cite this article as: M. Arora, et al., Blood Cells Mol. Diseases (2014), http://dx.doi.org/10.1016/j.bcmd.2014.07.008
